The latest on adalimumab availability in 2026

If you take adalimumab for a condition like rheumatoid arthritis, Crohn's disease, or psoriasis, you may have heard concerns about drug shortages. With headlines about medication supply problems affecting everything from ADHD drugs to antibiotics, it's natural to wonder: is adalimumab in shortage too?

Here's the current picture and what you can do to stay ahead of any access issues.

Is adalimumab still in shortage?

As of early 2026, adalimumab is not on the FDA or ASHP drug shortage lists. The medication — both brand-name Humira and its many biosimilars — is being actively manufactured and distributed across the United States.

That said, "not in shortage" doesn't always mean "easy to find." Individual pharmacies may not stock your specific version, and insurance requirements can create delays that feel like a shortage even when the drug is available. For a deeper look at why, read Why Is Adalimumab So Hard to Find?

Why is adalimumab still hard to find for some patients?

Even without a formal shortage, several factors can make it difficult to get your adalimumab on time:

Formulary changes and biosimilar switching

Insurance companies are aggressively shifting patients from brand-name Humira to lower-cost biosimilars. Some major pharmacy benefit managers (PBMs), including Express Scripts, removed Humira from their preferred formularies in 2025 in favor of biosimilars like Cyltezo or Hadlima. If your pharmacy stocks one biosimilar but your insurance now requires a different one, there's a mismatch that causes delays.

Specialty pharmacy requirements

Most insurance plans require adalimumab to be dispensed through a specialty pharmacy. If your prescription was sent to a retail pharmacy, it may be rejected or delayed. Specialty pharmacies typically coordinate directly with your insurance and ship to your home.

Prior authorization delays

Adalimumab almost always requires prior authorization (PA) from your insurance company. If your PA expires or your insurance changes, you may face a gap while the new authorization is processed. This can take days to weeks.

Cold-chain logistics

Adalimumab must be refrigerated at all times. Shipping and storage complications — especially during extreme weather — can occasionally disrupt the supply chain at the local level.

What does adalimumab cost in 2026?

Cost remains one of the biggest barriers to adalimumab access. Here's what you can expect:

• Brand-name Humira: Approximately $7,000 to $11,000 per month (cash price for 2 pens of 40 mg)
• High-price biosimilars (branded Hyrimoz, Cyltezo, Yuflyma): $3,500 to $6,500 per month at list price
• Low-price biosimilars (unbranded Hadlima, unbranded Hyrimoz): $1,300 to $1,900 per month at list price

With insurance, most patients pay significantly less — often $5 to $100 per month with copay assistance. Without insurance, the cash price can be a serious barrier. For money-saving strategies, see How to Save Money on Adalimumab in 2026.

New options for patients in 2026

The adalimumab market has changed dramatically since Humira was the only option. Here's what's new:

More interchangeable biosimilars

As of 2026, at least seven adalimumab biosimilars have received interchangeable status from the FDA: Amjevita, Cyltezo, Hadlima, Hyrimoz, Hulio, Simlandi, and Yuflyma. This means your pharmacist may be able to substitute one for another — making it easier to find some version of adalimumab in stock, even if your preferred brand isn't available.

Lower-cost unbranded versions

Several manufacturers offer unbranded (lower-list-price) versions of their biosimilars. These have the same active drug but a simpler label and lower price, which can translate to lower out-of-pocket costs — especially for patients without insurance or with high-deductible plans.

Expanding insurance coverage

More insurance plans are covering adalimumab biosimilars with favorable copays. Some plans, like Blue Shield of California, have partnered with biosimilar manufacturers to offer $0 out-of-pocket adalimumab for eligible members.

How to find adalimumab in stock right now

If you need adalimumab and your pharmacy doesn't have it, here's what to do:

1. Search on Medfinder to see real-time availability at pharmacies near you
2. Ask your pharmacist about interchangeable biosimilar substitution
3. Contact your specialty pharmacy to initiate or expedite your refill
4. Call your doctor's office if you need a new prior authorization or prescription update
5. Plan ahead: Start the refill process at least 7-10 days before your next dose

For a full step-by-step guide, read How to Find Adalimumab in Stock Near You.

Final thoughts

Adalimumab is not in a national shortage in 2026, but navigating the biosimilar market, insurance changes, and specialty pharmacy requirements can make it feel that way. The landscape is actually better than it was a few years ago — more options, more competition, and lower prices. The key is staying informed, planning ahead, and using tools like Medfinder to take control of your medication access.

If you're worried about your next refill, don't wait. Check availability today and talk to your care team about the options available to you.